A Randomized First-in-Human Study With UB-312, a UBITh® α-Synuclein Peptide Vaccine.
Hui Jing YuEva ThijssenEmilie van BrummelenJohan L van der PlasIgor RadanovicMatthijs MoerlandEric HsiehGeert Jan GroeneveldJean-Cosme DodartPublished in: Movement disorders : official journal of the Movement Disorder Society (2022)
UB-312 was generally safe, well tolerated, and induced anti-αSyn antibodies in serum and CSF of healthy participants. The 100 and 300 μg doses are selected for further evaluation in participants with PD. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.